Agilon Health, Inc. (AGL) Income Statement

The 7.2% YoY growth in 2026Q2 appears to be a rebound from the -7.3% contraction in 2026Q1, but the overall trend over the past year is decelerating, with quarterly growth rates ranging from -7.3% to 7.2%. This volatility likely stems from Medicare Advantage enrollment cycles and risk-adjustment changes, not organic acceleration. The raised guidance to $1,445M-$1,475M implies a sequential decline from the reported $1.5B quarter, indicating management's cautious outlook on membership growth.

The gross margin swing from -6.2% to 7.2% within two quarters highlights the volatility in medical claims, likely driven by utilization spikes in outpatient and pharmacy services. Despite the recent improvement, the negative gross margin in three of the last five quarters suggests that the company's capitation rates are insufficient to cover medical costs and provider incentives. This structural issue may indicate a lack of pricing power relative to payers and a need for more aggressive clinical management.

SG&A expenses have remained relatively stable in absolute terms, ranging from $54M to $88M, while revenue fluctuated between $1.4B and $1.6B. This suggests that the company's cost structure is not highly scalable, and the recent operating profit is primarily due to gross margin improvement rather than overhead efficiency. The lack of operating leverage implies that any future revenue growth may not translate into disproportionate profit growth unless SG&A is tightly controlled.

The company's cost structure is dominated by variable medical costs, which are difficult to control in the short term. The negative gross margin indicates that the company is paying out more in claims than it receives in capitation, a trend that has persisted for several quarters. While SG&A is relatively modest, the lack of R&D spending (reported as $0) suggests that the company is not investing in technology or care management solutions that could reduce medical costs over time.

The 2025Q4 results appear to be an outlier, with revenue of $1.6B but a gross loss of $97.6M, suggesting a sharp spike in medical claims or a one-time reserve adjustment. The subsequent recovery in 2026Q1 and Q2, with gross margins of 4.1% and 7.2%, indicates that the company may have addressed some cost pressures, but the sustainability of this improvement is uncertain. The lasting impact of this trough is a heightened focus on medical cost management, but the path to consistent profitability remains unclear.